Navigation Links
Rexahn to Use MedAvante Centralized Ratings in MDD Phase 2b Study

HAMILTON, N.J. and ROCKVILLE, Md., Oct. 26 /PRNewswire/ -- MedAvante, Inc., the leader in centralized expert evaluation of central nervous system (CNS) disorders, and Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN) a clinical stage pharmaceutical company developing and commercializing potential best in class oncology and CNS therapeutics, announced that Rexahn will use MedAvante 's Remote Centralized Ratings™ in their randomized, double-blind, placebo-controlled Phase 2b clinical study assessing the efficacy of Serdaxin® in patients with major depressive disorder (MDD).  MedAvante's centralized ratings were chosen to reduce bias and variability associated with CNS trials.

Rexahn is the latest in a growing number of pharmaceutical companies deciding to use centralized raters, who are free of study biases, for CNS trials. This approach has empirically demonstrated the ability to reduce rater variability and the placebo effect.

Centralized assessments in other therapeutic areas, including oncology, imaging and cardiovascular, are used to reduce bias and minimize variability and have been described affirmatively in regulatory guidance documents.  Now centralized calibrated raters conducting real-time psychiatric assessments are achieving the same benefits for sponsors of CNS studies.  

Rexahn's Serdaxin is a well characterized chemical entity tested for multiple CNS indications.  Data from a Phase 2a study in MDD has shown that Serdaxin has the potential to improve symptoms of depression, without the side effects commonly associated with currently marketed antidepressants.

"As a company seeking to develop and deliver new treatments for CNS disorders, it is vital that we design and conduct clinical trials that maximize rater objectivity and standardization," said Rick Soni, President and Chief Operating Officer of Rexahn.

"By their nature, depression trial results can be affected by any number of variables, especially when subjective assessments are used.  That is why having central raters who are continuously monitored and calibrated can minimize rater bias," said Soni.  "We carefully evaluated different methodologies and found MedAvante Remote Centralized Ratings far superior to traditional methods."

"Centralized ratings are the wave of the future in clinical testing of CNS drugs," said Paul M. Gilbert, Chief Executive Officer of MedAvante.  "Our centralized ratings are backed with extensive clinical operations experience, professional project management capabilities, and proprietary infrastructure – all working together to fit seamlessly into Rexahn's existing study research design.

"We are confident that our unique ability to deliver 'true' centralized ratings can significantly reduce the bias and ratings variability associated with typical CNS trials – thereby providing a true reflection of both treatment and placebo effect," said Gilbert.

MedAvante's centralized raters diagnose subjects and evaluate symptom severity to ensure appropriate patient ascertainment and post-baseline standardization, the most difficult challenges to signal detection in CNS studies.  The raters are mental health professionals with deep clinical and rating scale expertise, carefully selected through an intensive qualification process, and continuously trained and calibrated to ensure optimal inter-rater reliability and minimize rater drift, a factor leading to inconclusive results in CNS trials.

Having set up over 600 remote sites worldwide, MedAvante supports each with a robust rater scheduling system to ensure blinding, and 24/7 global technology support.  MedAvante automated systems are 21CFR (part 11) certified and data privacy protection is US/EU Safe Harbor compliant.

About MedAvante, Inc.

MedAvante is the premier global provider of centralized expert psychiatric rating and monitoring services to the pharmaceutical, biotechnology and medical device industries. Its flagship service, Remote Centralized Ratings, provides real-time assessments, either by telephone or videoconference, of subjects in global drug trials. Centralizing the assessors and blinding them to study protocols results in a level of standardization, calibration and objectivity that is not achievable with a decentralized group of study raters participating from unconnected investigative sites. In addition to Centralized Ratings, the company provides Continuous Quality Control (CQC), a monitoring service in which expert calibrated trainers review site-based study interviews via audio and video.  MedAvante solutions help sponsors achieve increased drug effect and reduced trial failure rates, enabling them to bring better drugs to market faster. MedAvante operates facilities in Hamilton, NJ; Madison, WI; and Moscow, Russia.  For more information, please visit

About Rexahn Pharmaceuticals, Inc.  

Rexahn Pharmaceuticals is a clinical stage pharmaceutical company dedicated to developing and commercializing best in class and market leading therapeutics for cancer, CNS disorders, sexual dysfunction and other unmet medical needs. Rexahn currently has three drug candidates in Phase II clinical trials, Archexin®, Serdaxin®, and Zoraxel™ – all potential best in class therapeutics – and a robust pipeline of preclinical compounds to treat multiple cancers and CNS disorders.  Rexahn also operates key R&D programs of nano-medicines, 3D-GOLD, and TIMES drug discovery platforms.  For more information, please visit

SOURCE MedAvante, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. MedAvante Launches Service to Boost Reliability of Assessments to Reduce Risk of Failed Alzheimers Disease Trials
2. MedAvante Opens Moscow Office and Successfully Completes First Centralized Ratings Assessment
3. ICON and MedAvante Sign Alliance Agreement
4. FDA Approves NDA That Includes Psychiatric Data Collected by Centralized Raters
5. ERT Announces New Report by TUFTS Identifying Growth in Adoption of Centralized ECG Services
6. Access MediQuip Announces Release of the Countrys First Centralized Recall Management Service(SM) for Implantable Devices
7. ERT Launches Centralized Cardiac Safety 2.0: A Revolutionary New Approach to ECG Management in Clinical Trials
8. New Database from ANSI, AAMI, ASTM International, and DIN Provides Centralized Source of Information for Medical Device Professionals
9. Decision Resources Forecast of Global Tanezumab Sales Slashed Following FDA Halt of Phase III Studies
10. Keryx Biopharmaceuticals Announces Completion of Patient Enrollment In Zerenex Phase 3 Short-Term Study
11. Sanofi-aventis Initiates Phase III Study with Teriflunomide as Adjunct Therapy with Interferon Beta to Further Explore Clinical Benefits in Multiple Sclerosis
Post Your Comments:
(Date:11/26/2015)... Nov. 26, 2015 Research and Markets ( ... "Advanced Wound Care Market by Type (Dressings, Therapy Devices, ... (In-Patient Facility, Out-Patient Facility), and Geography - Global Forecast ... --> --> The purpose ... and forecast of the global advanced wound care market. ...
(Date:11/26/2015)... India , November 26, 2015 ... --> adds ... Report" and "Investigation Report on China ... and 2021 forecasts data and information ... . ...
(Date:11/26/2015)... , Nov. 26, 2015 Research ... addition of the "2016 Future Horizons and ... (TDM) Market: Supplier Shares, Country Segment Forecasts, Competitive ... --> --> ... analysis of the Italian therapeutic drug monitoring market, ...
Breaking Medicine Technology:
(Date:11/26/2015)... ... November 26, 2015 , ... Health-E-minds ... collaborated with Women’s Web – an online resource for Indian women looking ... and emotional well-being relationship, life balance, stress, professional development, and lifestyle. Health-E-minds ...
(Date:11/25/2015)... ... 25, 2015 , ... The holiday season is jam-packed with ... palates of attendees is of the utmost importance. Whether you are cooking at ... these recipes a try this holiday season. , Turkey Croquettes , ...
(Date:11/25/2015)... ... November 25, 2015 , ... Dr. John Pierce, Medical Director at the Ageless ... treatment with the Capillus272™ Pro laser therapy cap. FDA cleared for safety and efficacy, ... without the need for surgery, prescription pills, or topical foams. , “Capillus272™ Pro ...
(Date:11/25/2015)... ... 25, 2015 , ... According to an article published November 10th ... widely heralded as a breakthrough for performing hernia repairs. The article explains that the ... is that it can greatly reduce the pain that a patient might otherwise experience ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... athletic programs, launches new Wimbledon Athletics Facebook page to educate the ... for unsuspected cardiac abnormalities. About 2,000 people under the age of 25 die ...
Breaking Medicine News(10 mins):